Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07812116 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07812116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 13, 2026
Completion date
November 8, 2030
Enrollment
156 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis